Last reviewed · How we verify
ropinirole CR-RLS
Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to reduce the abnormal motor symptoms of restless legs syndrome.
Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to reduce the abnormal motor symptoms of restless legs syndrome. Used for Restless legs syndrome (RLS).
At a glance
| Generic name | ropinirole CR-RLS |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Dopamine D2/D3 receptor agonist |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Ropinirole binds to and activates dopamine D2 and D3 receptors in the central nervous system. In restless legs syndrome, dopaminergic dysfunction contributes to the characteristic sensations and involuntary movements; dopamine agonism helps restore normal motor control and reduces the urge to move the legs. The CR (controlled-release) formulation provides sustained drug delivery for once-daily dosing.
Approved indications
- Restless legs syndrome (RLS)
Common side effects
- Nausea
- Dizziness
- Somnolence
- Headache
- Fatigue
- Orthostatic hypotension
- Hallucinations
Key clinical trials
- Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) (PHASE3)
- Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome (PHASE2)
- Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food (PHASE1)
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's (PHASE3)
- 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropinirole CR-RLS CI brief — competitive landscape report
- ropinirole CR-RLS updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI